GeneDx (NASDAQ:WGS) stock is taking a beating on Friday after the company revealed a proposed public stock offering.
According to a press release, GeneDx intends to raise $150 million from the offering. The company doesn’t say how many shares will be included in the public offering, or what price shares will be sold at.
What GeneDx does say is that all of the shares will be sold directly. Also, the company intends to allow underwriters to acquire additional shares in the offering. That would come in at 15% of the number of shares included in the offering. Jefferies is acting as the book-running manager and Cowen is the financial advisor for the offering.
GeneDx already has plans for the funds from the public WGS stock offering. The company intends to use the money for “general corporate purposes.” That includes as working capital, for repayment of debts and for strategic investments.
Why WGS Stock Is Falling
Investors don’t often react well to news of a proposed public stock offering. That makes sense, as offerings increase the amount of outstanding stock. This dilutes the stakes of current shareholders. These kinds of offerings are also often below the stock’s market price.
WGS stock is down 8.1% as of Friday morning.
There’s more recent stock market news worth diving into below!
InvestorPlace is home to all of the latest stock market coverage for Friday! That includes why shares of ContraFect (NASDAQ:CFRX), Akanda (NASDAQ:AKAN) and Redhill Biopharma (NASDAQ:RDHL) stock are moving today. You can catch up on all that news at the following links!
More Friday Stock Market News
- Why Is ContraFect (CFRX) Stock Down 23% Today?
- Why Is Akanda (AKAN) Stock Up 31% Today?
- Why Is Redhill Biopharma (RDHL) Stock Up 32% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
